NFΚB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Walker Caulfield, Margaret E ^a   Guo, Yong ^a   Johnson, Renee K ^a   McCarthy, Christina B ^a   Fitz Gibbon, Patrick D ^a   Lucchinetti, Claudia F ^a   Howe, Charles L ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Bortezomib; NF B; NMO; PR 957; Reactive astrocyte

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; PARAFFIN; PR 957; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; OLIGOPEPTIDE; PR-957;

ANIMAL CELL; ARTICLE; ASTROCYTE; AUTOPSY; CELL INFILTRATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MYELOOPTIC NEUROPATHY; NERVE CELL CULTURE; NERVE CELL STIMULATION; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GLIA; IMMUNOLOGY; METABOLISM; MOUSE; NEUTROPHIL CHEMOTAXIS; NEWBORN; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; BORTEZOMIB; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GRANULOCYTES; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUROGLIA; NEUROMYELITIS OPTICA; NEUTROPHIL INFILTRATION; NF-KAPPA B; OLIGOPEPTIDES; PROTEASOME INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84942577777     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0403-8     Document Type: Article

References (54)

1. Pereira WL, Reiche EM, Kallaur AP, Kaimen-Maciel DR. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. J Neurol Sci. 2015;355(1-2):7-17. doi: 10.1016/j.jns.2015.05.034.
2. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149-64. doi: 10.1111/cei.12271.
3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-7. doi: 10.1084/jem.20050304.
4. Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol. 2013;23(6):684-95. doi: 10.1111/bpa.12085.
5. Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14(4):265-77. doi: 10.1038/nrn3468.
6. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964-8. doi: 10.1001/archneur.63.7.964.
7. Howe CL, Kaptzan T, Magana SM, Ayers-Ringler JR, LaFrance-Corey RG, Lucchinetti CF. Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia. 2014;62(5):692-708. doi: 10.1002/glia.22635.
8. Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83-97. doi: 10.1111/bpa.12099.
9. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gomez JA, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76(14):1229-37. doi: 10.1212/WNL.0b013e318214332c. WNL.0b013e318214332c [pii].
10. Nytrova P, Potlukova E, Kemlink D, Woodhall M, Horakova D, Waters P, et al. Complement activation in patients with neuromyelitis optica. J Neuroimmunol. 2014;274(1-2):185-91. doi: 10.1016/j.jneuroim.2014.07.001.
11. Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10(9):493-506. doi: 10.1038/nrneurol.2014.141.
12. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7:185-217. doi: 10.1146/annurev-pathol-011811-132443.
13. Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron. 2014;81(2):229-48. doi: 10.1016/j.neuron.2013.12.034.
14. Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015;16(5):249-63. doi: 10.1038/nrn3898.
15. Pekny M, Wilhelmsson U, Pekna M. The dual role of astrocyte activation and reactive gliosis. Neurosci Lett. 2014;565:30-8. doi: 10.1016/j.neulet.2013.12.071.
16. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121-30.
17. Wang F, Smith NA, Xu Q, Fujita T, Baba A, Matsuda T, et al. Astrocytes modulate neural network activity by Ca(2)+-dependent uptake of extracellular K+. Sci Signal. 2012;5(218):ra26. doi: 10.1126/scisignal.2002334.
18. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32(18):6391-410. doi: 10.1523/JNEUROSCI.6221-11.2012.
19. Kramer A, Green J, Pollard Jr J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30(4):523-30. doi: 10.1093/bioinformatics/btt703.
20. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-17. doi: 10.1056/NEJMoa030288.
21. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009;15(7):781-7. doi: 10.1038/nm.1978.
22. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64(2):493-503. doi: 10.1002/art.33333.
23. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1-2):82-90. doi: 10.1016/j.jns.2011.03.038.
24. Milano E, Di Sapio A, Malucchi S, Capobianco M, Bottero R, Sala A, et al. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. Neurol Sci. 2003;24(3):130-3. doi: 10.1007/s10072-003-0098-y.
25. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS ONE. 2013;8(4), e61835. doi: 10.1371/journal.pone.0061835.
26. Michael BD, Elsone L, Griffiths MJ, Faragher B, Borrow R, Solomon T, et al. Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms - a pilot study. Cytokine. 2013;64(1):90-6. doi: 10.1016/j.cyto.2013.07.019.
27. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16(12):1443-52. doi: 10.1177/1352458510379247.
28. Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol. 2014;24(1):67-73. doi: 10.1111/bpa.12097.
29. Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology. 2004;63(12):2363-70.
30. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450-61.
31. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0.
32. Sun SC, Chang JH, Jin J. Regulation of nuclear factor-kappaB in autoimmunity. Trends Immunol. 2013;34(6):282-9. doi: 10.1016/j.it.2013.01.004.
33. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol. 2010;88(1):117-22. doi: 10.1189/jlb.1009666.
34. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A. 2004;101(21):8120-5. doi: 10.1073/pnas.0401563101.
35. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748-55. doi: 10.1038/nm1763.
36. Merin NM, Kelly KR. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharm. 2014;8(1):1-20. doi: 10.3390/ph8010001.
37. Gomez AM, Willcox N, Vrolix K, Hummel J, Nogales-Gadea G, Saxena A, et al. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol. 2014;193(3):1055-63. doi: 10.4049/jimmunol.1301555.
38. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol. 2008;180(1):361-71.
39. Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617-29. doi: 10.1002/ana.21802.
40. Kowarik MC, Dzieciatkowska M, Wemlinger S, Ritchie AM, Hemmer B, Owens GP, et al. The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J Neuroinflammation. 2015;12:19. doi: 10.1186/s12974-015-0240-9.
41. Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, et al. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med. 2014;6(2):226-38. doi: 10.1002/emmm.201303543.
42. Jansen AH, Reits EA, Hol EM. The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. Front Mol Neurosci. 2014;7:73. doi: 10.3389/fnmol.2014.00073.
43. Kisselev AF, Groettrup M. Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Curr Opin Chem Biol. 2014;23:16-22. doi: 10.1016/j.cbpa.2014.08.012.
44. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630-43. doi: 10.1002/ana.21837.
45. Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler. 2012;18(4):398-408. doi: 10.1177/1352458512440060.
46. Jones MV, Huang H, Calabresi PA, Levy M. Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathol Commun. 2015;3:28. doi: 10.1186/s40478-015-0207-1.
47. Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71(3):323-33. doi: 10.1002/ana.22686.
48. Asavapanumas N, Ratelade J, Papadopoulos MC, Bennett JL, Levin MH, Verkman AS. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation. 2014;11:16. doi: 10.1186/1742-2094-11-16.
49. Zhang H, Verkman AS. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J Autoimmun. 2014;53:67-77. doi: 10.1016/j.jaut.2014.02.011.
50. Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, et al. Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol Commun. 2013;1(1):5. doi: 10.1186/2051-5960-1-5.
51. Jacob A, Saadoun S, Kitley J, Leite M, Palace J, Schon F, et al. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. Mult Scler. 2012;18(12):1801-3. doi: 10.1177/1352458512443994.
52. Walker-Caulfield ME, Hatfield JK, Brown MA. Dynamic changes in meningeal inflammation correspond to clinical exacerbations in a murine model of relapsing-remitting multiple sclerosis. J Neuroimmunol. 2015;278:112-22. doi: 10.1016/j.jneuroim.2014.12.009.
53. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9-22. doi: 10.1038/nri3341.
54. Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72(8):712-7. doi: 10.1212/01.wnl.0000343001.36493.ae.